ReviewMolecular diagnosis & therapy2014
Reverse phase protein arrays: mapping the path towards personalized medicine.
Review in Molecular diagnosis & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction.NPJ precision oncology · 2025Article
- Building Reversed-Phase Microarrays on Low-Cost Biosensing Chips: Application to Multiplexed Detection of Food Allergies.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.British journal of cancer · 2024Article
- Histopathology and proteomics are synergistic for High-Grade Serous Ovarian Cancer platinum response prediction.medRxiv : the preprint server for health sciences · 2024Article
- Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.Cancer science · 2024Review
- Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancer.Scientific reports · 2023Article
- Gene expression profiles of ischemic stroke clots retrieved by mechanical thrombectomy are associated with disease etiology.Journal of neurointerventional surgery · 2023Article
- Reversed-phase allergen microarrays on optical discs for multiplexed diagnostics of food allergies.Mikrochimica acta · 2023Article
- Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach.Cell reports methods · 2022Article
- The active kinome: The modern view of how active protein kinase networks fit in biological research.Current opinion in pharmacology · 2022Review
- Reverse phase protein arrays in acute leukemia: investigative and methodological challenges.Expert review of proteomics · 2021Review
- Article
- The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia.Journal of proteomics · 2021Article
- Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification.Molecular & cellular proteomics : MCP · 2021Review
- Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies.Scientific reports · 2020Article
- Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient.Scientific reports · 2020Article
- A pre-existing population of ZEB2Journal of experimental & clinical cancer research : CR · 2020Article
- Proteomics for cancer drug design.Expert review of proteomics · 2019Article
- Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models.Frontiers in oncology · 2019Article
- Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma.Radiation oncology (London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Reverse phase protein array (RPPA) technology evolved from the advent of miniaturized immunoassays and gene microarray technology. Reverse phase protein arrays provide either a low throughput or high throughput methodology for quantifying proteins and their post-translationally modified forms in both cellular and non-cellular samples. As the demand for patient tailored therapies increases so does the need for precise and sensitive technology to accurately profile the molecular circuitry driving an individual patient's disease. RPPAs are currently utilized in clinical trials for profiling and comparing the functional state of protein signaling pathways, either temporally within tumors, between patients, or within the same patients before/after treatment. RPPAs are generally employed for quantifying large numbers of samples on one array, under identical experimental conditions. However, the goal of personalized cancer medicine is to design therapies based on the molecular portrait of a patient's tumor, which in turn result in more efficacious treatments with less toxicity. Therefore, RPPAs are also being validated for low throughput assays of individual patient samples. This review explores RPPA technology in the cancer research field, concentrating on its role as a fundamental tool for deciphering protein signaling networks and its emerging role in personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.